Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation

Table 1 Description of the study cohort and baseline CSF biomarker data

	All (n = 80)	Aβ+¹ (n = 38)	Aβ−¹ (n = 42)	p-value²
Age [years, median ± MAD]	68 ± 8.9	71 ± 7.4	65 ± 5.9	0.0056
Female	46 (57.5%)	23 (60.53%)	23 (54.76%)
Male	34 (42.5%)	15 (39.47%)	19 (45.24%)
ApoE4 carrier	37 (46.25%)	29 (76.3%)	8 (19.05%)
CSF Aβ42/40 [median ± MAD]	0.062 ± 0.031	0.036 ± 0.008	0.078 ± 0.010	< 0.0001
CSF Aβ42 [pg/mL, median ± MAD]	706.5 ± 354.3	467.5 ± 161.6	893.0 ± 276.5	< 0.0001
CSF Aβ40 [pg/mL, median ± MAD]	11820.0 ± 3724.3	12423.0 ± 4548.6	10835.5 ± 3407.8	0.0803
CSF t-Tau [pg/mL, median ± MAD]	328.0 ± 197.2	476.5 ± 172.7	205.0 ± 71.9	< 0.0001
CSF pTau-181 [pg/mL, median ± MAD]³	51.7 ± 23.9	74.6 ± 23.7	36.5 ± 9.9	< 0.0001

¹The clinical sample was dichotomized according to the CSF Aβ42/Aβ40 ratio. Aβ-positive (Aβ+): CSF Aβ42/40 ≤ 0.050; Aβ-negative (Aβ−): CSF Aβ42/40 > 0.050
²Mann-Whitney-test p-values for the comparison between the groups Aβ+ and Aβ−
³In one case, the pTau 181 concentration was reported as <15.6 pg/mL. To be included in the statistical analysis, this value was artificially set to a fixed value of 15.6 pg/mL
Aβ amyloid-β, CSF cerebrospinal fluid, MAD median absolute deviation scaled with factor 1.4826, pTau phospho-Tau, t-Tau total Tau

ISSN: 1758-9193